Évaluation de l’imatinib dans la prise en charge de la leucémie myéloïde chronique au Gabon À propos de dix-sept cas Volume 26, numéro 2, Avril-Mai- Juin. REVUE MEDICALE DE LIEGE. Cliquer ICI pour déclencher le téléchargement de l’article. COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE. Résumé La leucémie myéloïde chronique (LMC) est un modèle de cancérogenèse. Son pronostic a été exceptionnellement amélioré grâce.
|Published (Last):||27 November 2017|
|PDF File Size:||12.28 Mb|
|ePub File Size:||12.78 Mb|
|Price:||Free* [*Free Regsitration Required]|
As per the Law relating to information storage and personal integrity, you have the right to oppose art 26 of leucwmie lawaccess art 34 of that law and rectify chroniquf 36 of that law your personal data. Access to the text HTML. Journal page Archives Contents list. If you are a subscriber, please sign in ‘My Account’ at the top right of the screen.
Top of the page – Article Outline. New strategies to eradicate these residual cells by targeting the hematopoietic niche or directly the leukemic stem cells are being developed. N Engl J Med. Chronic myeloid leukaemia in South African blacks. The chroniqud of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Personal information regarding our website’s visitors, including their identity, is confidential. An experience from eastern India. Chronic myeloid leukemia advances in biology and new approaches to treatment.
Leucémie myéloïde chronique
Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi. Contact Help Who are we? Access to the PDF text.
Outline Masquer le plan. New technologies digital PCR, high-throughput sequencing or NGS were developed to improve the performances of existing methods. Molecular biology of bcr-abl1-positive CML. International recommendations facilitate the management of CML chroniqeu treatment adjustments. Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction.
Médecine et Santé Tropicales
Hematologic and cytogenetic response to Imatinib mesylate in chronic myelogenous leukemia. A retrospective study of leukemia epidemiology in Northern Tunisia. Indian J Hematol Blood Transfus.
Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia. Access to the full text of this article requires a subscription. S Af Med J. Clinical and pronognostic features of Nigerians with chronic myeloid leukemia. Chronic myeloid leukaemia in central Africans.
Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Les inhibiteurs des kinases.
If you want to subscribe to this journal, see our rates You can purchase this item in Pay Per View: For the remaining half of patients, the causes leading to the molecular relapse deserve to be further analyzed. Clinical trials have validated TKI discontinuation strategies in patients with sustained deep molecular response. Finally, the immune system undoubtedly plays a crucial function in the control of residual leukemic cells; this role should be specified in the future.
Leucémie myéloïde chronique | Blausen Medical
Acellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. East Afr Med J.
You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted. You can move this window by clicking on the headline. Tyrosine kinase inhibitor TKI therapy imatinib, dasatinib, nilotinib, bosutinib, ponatinib has led to improved overall myloide disease-free survival of patients. Imatinib mesylate therapy in patients of chronic leuucemie leukemia with Philadelphia chromosome positive: The persistence of TKI-refractory leukemic stem cells could explain this result.
The Glivec international patient assistance programme: